# Moderna stock is showing upward bias.

*biotech · news · 2026-05-08 · Benzinga*

## Key points

- Moderna's stock is currently trading 2.7% below its 20-day SMA and 4.8% below its 50-day SMA.
- A golden cross formed in January but near-term moving averages suggest a paused uptrend.
- Moderna's mRNA-1010 flu vaccine Phase 3 results are seen as critical for non-pandemic revenue prospects.
- Key technical levels are $47.50 as support and $55.00 as resistance for MRNA stock.

**Companies:** Moderna
**Countries:** United States

[Read the full story on Benzinga](https://www.benzinga.com/trading-ideas/movers/26/05/52408328/moderna-stock-rises-on-positive-phase-3-flu-data-what-investors-need-to-know)

---

Canonical: https://newsio.io/n/e51e71a0-0d82-4f93-a602-5533beed6612/moderna-stock-is-showing-upward-bias-momentum-looks-more-reset-than-breakout-rig
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works